Hydroxyapatite vs Fluoride Toothpaste in Human Clinical Trials
A PubMed-based structured secondary review of comparative human toothpaste studies published from 2010 through 13 September 2026.
The bottom line
Hydroxyapatite toothpaste has encouraging human clinical evidence, but the strength and meaning of that evidence differ by outcome. Three fluoride-free hydroxyapatite trials met their own prespecified non-inferiority criteria against fluoride toothpaste for particular caries outcomes. Several mostly short trials reported reduced dentin hypersensitivity. Evidence for periodontal benefit was limited, and this search found no eligible direct comparative human home-use trial supporting a direct whitening or erosion claim.
The responsible conclusion is outcome-specific: the evidence does not justify treating all hydroxyapatite products, populations and oral-health claims as interchangeable.
What the evidence showed
Caries prevention
In three studies, fluoride-free hydroxyapatite toothpaste achieved prespecified non-inferiority criteria against fluoride toothpaste for product-, population- and outcome-specific caries endpoints. The trials used different measures and margins, so this does not establish universal equivalence.
Dentin hypersensitivity
Multiple short randomized trials reported reduced dentin hypersensitivity with hydroxyapatite toothpastes versus placebo, fluoride or active desensitizing toothpastes. Most lasted four to eight weeks, and formulations and outcome tests varied.
Periodontal outcomes
The one eligible periodontal trial found no significant hydroxyapatite advantage over an amine-fluoride/stannous-fluoride toothpaste for plaque formation or clinical periodontal outcomes.
Whitening and erosion
No eligible direct comparative human home-use hydroxyapatite toothpaste trial supported a direct whitening claim in this PubMed search. Screened erosion studies did not isolate the effect of hydroxyapatite toothpaste against a no-hydroxyapatite toothpaste.
Safety
The included trials can describe reported adverse events, but they are not sufficient to establish rare or long-term safety across all users. An absence of observed adverse events in a trial should not be turned into a broad safety guarantee.
Funding and conflict context
At least 8 of the 17 eligible studies were confirmed as manufacturer-linked. Funding was unclear from accessible declarations for another 7 studies, while 2 declared no external support or nil support. The confirmed 47% is therefore a minimum, not a definitive estimate of all industry involvement.
Industry involvement does not automatically invalidate a study. It does make transparent declarations, independent replication and careful interpretation especially important.
How the review was conducted
| Review question | What comparative human clinical outcomes have been reported for hydroxyapatite-containing toothpaste versus fluoride toothpaste, placebo toothpaste or no-hydroxyapatite toothpaste? |
|---|---|
| Database | PubMed |
| Search window | 1 January 2010 through 13 September 2026 |
| Included | Human participants; routine home use of hydroxyapatite or nano-hydroxyapatite toothpaste; an eligible comparator; at least four weeks; original comparative data; and a plainly reportable patient-level outcome. |
| Excluded | Laboratory-only or extracted-tooth studies; in-situ specimen outcomes; uncontrolled studies; follow-up under four weeks; reviews or opinions; untranslated non-English reports; and regimens in which the toothpaste effect could not be separated. |
| Outcome handling | Caries, sensitivity, periodontal, erosion, whitening, microbiology and other outcomes were assessed as separate evidence streams. Results were described, not pooled. |
Limitations
- This was a structured secondary evidence review based on one database, PubMed.
- The review was not prospectively registered.
- It did not include a formal risk-of-bias instrument or meta-analysis.
- Search strings overlapped, so their individual result counts cannot be added together.
- Funding classifications reflect declarations accessible during the review; an unclear declaration does not prove independence.
- A study not identified in this search may still exist outside PubMed or outside the stated eligibility rules.
Clinical review
Dr Mohammad Ibtehaz Alam, BDS, PhD
Dr Alam evaluated 14 proposed publication claims against the supplied evidence ledger. He approved 11 as written and revised 3; no claims were deleted. The revised wording is reflected in the final report and this page.
Scope disclosure: this credit does not mean that Dr Alam independently repeated the database search, study selection or data extraction. It should not be represented as journal peer review or authorship of the complete report.
Read the complete evidence record
The full 19-page report contains the publication-ready claims and their mandatory caveats, the complete included-study ledger, funding declarations, auditable PubMed search log, exclusion log and source register.
Suggested citation
VerdictLab. Hydroxyapatite vs Fluoride Toothpaste in Human Clinical Trials 2010–2026: A PubMed-Based Structured Secondary Evidence Review. Version 1.0. 18 September 2026. Zenodo. https://doi.org/10.5281/zenodo.22834749